Opinion

Video

Role of Allogeneic Transplants in Hematologic Malignancies

Author(s):

Miguel-Angel Perales, MD,Nelli Bejanyan, MD

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.

The discussion focuses on the role of allogeneic hematopoietic stem cell transplantation in hematologic malignancies, particularly acute myeloid leukemia and acute lymphoblastic leukemia (ALL). Despite the advent of novel therapies, allogeneic transplantation remains the only curative option for many patients with high-risk features. Data from the Center for International Blood and Marrow Transplant Research shows improved outcomes for ALL patients undergoing allogeneic transplantation over time. The increasing use of alternative donors has made it possible for most patients in need of transplantation to find a suitable donor.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Rachel N. Grisham, MD
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Julie M. Vose, MD, MBA
Alberto Chiappori, MD
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
Related Content
Ajay Goel, PhD, AGAF, professor, chair, Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope in Duarte, California
March 19th 2025

CA19-9 Plus Liquid Biopsy Represents Diagnostic Biomarker of Interest for Early-Stage Pancreatic Cancer Detection

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
February 17th 2025

Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

Andreas M. Kaiser, MD, professor, chief, Division of Colorectal Surgery, Department of Surgery, City of Hope
March 18th 2025

Minimally Invasive Surgical Approaches Are a Convenient and Effective CRC Management Option

Mark B. Geyer, MD, Adolescent and Young Adult Program leader, Adult Lymphoblastic Leukemia Program leader, Leukemia Service, chair, Quality Assessment, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center; Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
February 10th 2025

Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD

Acute Myeloid Leukemia | Image Credit: © stock.adobe.com
March 12th 2025

INB-100 Following HSCT Displays Long-Lasting Activity in Pretreated AML

Brian Czerniecki, MD
March 11th 2025

Moffitt Study Identifies Immune Response That May Stop Breast Cancer from Spreading